Here are three stocks that analysts say are primed for huge out-sized growth in the next 12 months. Biotech stocks often present intriguing investment opportunities- although the rewards can be quickly eradicated if key regulatory approvals are delayed or refused. To minimize the risk, we specifically searched for stocks with a high degree of confidence from top analysts.

In this case, we used the popular Trending Stocks tool to filter for best-rated stocks in the last week and with any market cap size. We crunched the data and pinpointed these three compelling stocks that are trending right now.

You can also see the average analyst price target and in green the upside percentage from the current share price. This is a crucial indicator of price potential over the next 12 months. All three stocks share a ‘Strong Buy’ analyst consensus rating.

Let’s delve deeper into why the Street is so bullish on these stocks now:

TG Therapeutics 

TG Therapeutics (Nasdaq:TGTX) is focused on the development of novel treatments for B-cell malignancies and autoimmune diseases. Following strong Q4 results, five-star HC Wainwright analyst Edward White ramped up his price target from $33 to $38 on March 8.

He explains: “We use the net present value of our revenue forecast through 2026, apply a 55% probability of success (POS) for ublituximab in CLL (Chronic Lymphocytic Leukemia), a 45% POS for umbralisib in CLL, and a 25% POS for both ublituximab and umbralisib in NHL (Non-Hodgkin Lymphoma), to arrive at our $38 price target.”

Bear in mind that so far White has struck gold with his TGTX recommendations. Across his 20 ratings on the stock he scored a 90% success rate and 44.4% average return. Meanwhile B.Riley FBR’s Madhu Kumar selects TGTX as an Out the Gate 2018 Pick, due to his “reasonable confidence in success in the Phase III UNITY-CLL trial, with interim data expected in 2Q18.”

TherapeuticsMD

Innovative women’s healthcare company, TherapeuticsMD (NYSE:TXMD), has just scored an important regulatory win. The FDA has announced that it is accepting an NDA (new drug application) for TX-001HR without noting any ‘potential review issues.’ Now the key date to keep an eye on is October 28 2018, when the FDA will either approve or reject the application.

“We view the revenue opportunity for TX-001 (hot flushes of menopause) to be several times larger than that for TX-004 and believe prevailing compounding regulations and compounder willingness to prescribe branded drugs could benefit TXMD” states top Cantor Fitzgerald analyst William Tanner. He sees the stock spiking a whopping 400% to hit $28 from the current share price of just $5.50.

In the meantime, TXMD’s other pipeline product, TX-004, has its approval date on May 29. Tanner sees this as a critical barometer for TX-001 and says “we view the importance of the FDA’s action around that date to be of Brobdingnagian proportion.”

Flex Pharma

Last but not least comes ‘Strong Buy’ stock Flex Pharma (Nasdaq:FLKS). Flex develops treatments for cramps and spasms associated with severe neurological diseases including ALS, MS and CMT (Charcot–Marie–Tooth disease).

Top HC Wainwright analyst Andrew Fein has just reiterated his Flex buy-rating with a very bullish $40 price target. Given that the stock is currently trading at just $5, this indicates huge upside potential of over 680%. ”Catalysts on deck in MS, ALS, and CMT may provide near-term inflection points” according to Fein. Most notably, read out data from FLX-787’s exploratory Phase 2 spasticity study in multiple sclerosis is due later this month.

“All these activities in the pipeline may provide near-term inflection points, and signal to us that the company is making points, and signal to us that the company is making solid strides, and is committed, to transitioning into a pharmaceutical company from a consumer company” cheered Fein on March 8.